21:27 , Aug 23, 2019 |  BC Extra  |  Clinical News

GSK notches clinical win with anti-BCMA ADC amid cancer pipeline push

GlaxoSmithKline's return to cancer took another large step forward as one of its most prominent oncology candidates succeeded in a pivotal Phase II trial to treat multiple myeloma. On Friday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said...
00:59 , Aug 22, 2019 |  BC Extra  |  Company News

Aug. 21 Company Quick Takes: GSK, FibroGen take regulatory steps forward for HIF-PH inhibitors in Asia; plus Xtandi, Biotheus/Alligator and more

GSK seeking approval of HIF-PH inhibitor in Japan  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it submitted an NDA to Japan's Ministry of Health, Labour and Welfare for daprodustat to treat patients with renal anemia due to...
21:59 , Aug 21, 2019 |  BC Extra  |  Company News

Interest in carbohydrate antigens grows with Siamab acquisition

Siamab's acquisition by an undisclosed pharma is the latest example of pharma's growing interest in targeting sugar groups to treat cancer. The announcement comes less than two years after the biotech teamed up with Boehringer...
00:53 , Aug 21, 2019 |  BC Extra  |  Financial News

Aug. 20 Financial Quick Takes: WuXi companies report increased profits; plus Graybug, Araris and Sarepta

WuXi AppTec and WuXi Biologics report interim revenues  WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) and WuXi Biologics Inc. (HKEX:2269) reported gross profits of RMB2.3 billion ($324 million) and RMB671 million ($95 million) in 1H19, up...
23:49 , Aug 20, 2019 |  BC Extra  |  Company News

Management tracks: uniQure, Provention, Anaptys, FDA and more

uniQure N.V. (NASDAQ:QURE) promoted CSO Sander van Deventer to EVP, research and product development and Alex Kuta to EVP, operations from SVP, regulatory affairs. As a result, the gene therapy company said COO Scott McMillan...
00:14 , Aug 20, 2019 |  BC Extra  |  Financial News

Aug. 19 Financial Quick Takes: Juvenescence raises $100M Series B; plus 10X, IGM propose IPOs

Juvenescence closes $100M series B  Juvenescence Ltd. (Douglas, Isle of Man) said it has closed its $100 million series B round and reiterated plans to seek an IPO. Investors included the company's founders plus Grok...
23:32 , Aug 15, 2019 |  BC Innovations  |  Translation in Brief

New target bolsters TREM2's role in Alzheimer's

A new gene linked to TREM2 reinforces the microglial receptor's role in Alzheimer's and could offer a way to treat the disease. As the Alzheimer's field looks beyond β amyloid for new pathways and targets,...
21:38 , Aug 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Melding bispecifics and CAR T cells to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer An anti-EGFRvIII CAR T cell engineered to secrete an anti-CD3, anti-EGFR bispecific antibody could treat glioblastoma. In a mouse model of EGFRvIII-positive or EGFRvIII-negative glioblastoma, the engineered cells decreased...
23:23 , Aug 12, 2019 |  BC Extra  |  Company News

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

Jazz gains essential tremor asset via Cavion takeout   Jazz Pharmaceuticals plc (NASDAQ:JAZZ) acquired Cavion Inc. for $52.5 million up front and up to $260 million in clinical, regulatory and sales milestones in a deal...
02:02 , Aug 10, 2019 |  BioCentury  |  Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...